Netlist narrows losses, posts Q2 revenue and margin gains; legal, cash and inventory risks remain

Netlist, Inc. (NASDAQ: NLST)

Quick read: Netlist reported Q2 2025 results showing revenue growth vs. Q2 2024, tighter gross margins, lower legal/R&D spend and a smaller quarterly loss. Liquidity improved through a June 2025 registered offering, but working capital is negative, inventories rose sharply and major patent litigation and a disclosed material weakness in internal controls remain significant overhangs.

Key facts & statistics (all figures in thousands, except per-share amounts and counts)
- Net sales Q2 2025: $41,706 (Q2 2024: $36,835) - +13%
- Net sales six months 2025: $70,681 (6M 2024: $72,642) - (3%)
- Gross profit Q2 2025: $1,392 (Q2 2024: $773) - +80%; gross margin Q2: 3% vs 2%
- Gross profit 6M 2025: $2,692 (6M 2024: $1,488) - +81%; gross margin 6M: 4% vs 2%
- Net loss Q2 2025: ($6,078) vs ($14,778) in Q2 2024; Net loss 6M 2025: ($15,565) vs ($31,746) 6M 2024
- Loss per share (basic & diluted) Q2 2025: ($0.02) vs ($0.06) prior year; 6M: ($0.06) vs ($0.12)
- Weighted-average shares outstanding (basic & diluted) 6M 2025: 274,065 (in thousands shown in table; company reports ~275,751 for Q2 calculation)
- Cash, cash equivalents and restricted cash at June 28, 2025: $29,038 (Dec 28, 2024: $34,607)
- Cash and cash equivalents at period end: $18,438; restricted cash: $10,600
- Net cash used in operating activities (6M 2025): ($17,732) - improved vs ($22,025) in 6M 2024
- Net cash provided by financing activities (6M 2025): $12,188 (includes June 2025 Offering net proceeds ~ $11.3M)
- Inventories: $8,781 (Dec 28, 2024: $2,744) - large increase due to finished goods build for orders shipped after quarter end
- Accounts payable: $33,373 (Dec 28, 2024: $42,307) - decrease
- Deferred revenue: $10,318 (Dec 28, 2024: $40) - significant increase (advance payments on orders shipped after quarter end)
- Total current liabilities: $48,013; total liabilities: $48,403
- Total assets: $41,445; stockholders' deficit: ($6,958) (Dec 28, 2024: ($6,048))
- Outstanding common shares (reported Aug 7, 2025): 292,464,426
- Warrants outstanding as of June 28, 2025: 59,034 (weighted avg exercise: $1.31)
- SVB revolving line outstanding borrowings as of June 28, 2025: $1,105; availability: $0
- March 2025 Lincoln Park facility: $75.0M capacity; $73.9M remains available as of June 28, 2025

Positive signals
- Revenue growth in Q2 YOY (+13%) and materially improved gross profit and margin percentages (gross profit Q2 +80%, margin up to 3%).
- Net loss narrowed substantially vs prior-year periods (Q2 loss fell from ($14.8M) to ($6.1M)).
- Operating expense discipline: large reductions in R&D and intellectual property legal fees vs. prior year (R&D Q2 $833 vs $2,369; IP legal fees Q2 $3,480 vs $10,514).
- Fresh capital: June 2025 registered offering raised net proceeds of ~ $11.3M; March 2025 Lincoln Park equity facility still provides liquidity optionality (~$73.9M unused).

Negative / risks - what management and investors should watch
- Working capital negative: working capital reported as (8,249) at June 28, 2025 - company remains reliant on equity raises and financing facilities.
- Inventory spike to $8,781 from $2,744 - tied to finished goods build for orders shipped after quarter end; risks: obsolescence, cash tied up, and margins if component prices move.
- Deferred revenue jump to $10,318 - indicates advance receipts for future shipments but also timing risk and fulfillment obligations.
- Customer & supplier concentration: top customer represented 34% of Q2 sales; Supplier A accounted for 93% of purchases (Q2) - concentration risk is high.
- Litigation overhang: multiple major patent cases (Samsung, Micron, Google) with prior jury awards ($303M, $118M, $445M reported in filings) but subject to appeals, IPRs and challenges - collection is uncertain and outcomes could change materially.
- Material weakness in internal control over financial reporting disclosed - lack of independent board/audit committee until June 2025; remediation is in progress but not yet proven.
- No availability under SVB credit line borrowing base ($0 availability) and continued dependence on equity financing (which dilutes shareholders) and warrant overhang (59,034 outstanding).
- Stockholders' deficit of ($6.96M) and continued history of net losses (company has recorded losses historically and only two profitable years since inception as noted in MD&A).

Operational notes / context
- Revenue mix: ~96% of net sales are resales of third-party products (Q2 2025), with the PRC billing location representing the majority of sales (PRC ~ $38,848 of Q2 sales).
- Management reduced R&D and IP litigation spend in 2025 vs. 2024, improving operating expense profile but IP activity is likely to continue on an episodic basis.
- Cash burn improved but remains material; company states existing resources plus financing facilities expected to be sufficient for at least 12 months - this is management guidance, not a guarantee.

Bottom line - What's happening inside Netlist
Netlist is stabilizing losses and improving gross margin through product mix and lower legal/R&D cash spend, while shoring up liquidity via a June 2025 equity raise and maintaining access to the Lincoln Park equity facility. However, balance-sheet stress remains: working capital is negative, inventories ballooned, supplier/customer concentration is high, and substantial legal risk and a disclosed material weakness in controls create headline and execution risk. The company is between stages: revenue and margin signals are constructive, but capital and legal outcomes will determine whether Netlist can convert operational improvements into sustained profitability.

If you want, I can prepare a 1-page investor note that prioritizes near-term catalysts (litigation milestones, warrant/exercise timelines, inventory digestion/shipments, liquidity runway) and model the cash runway under a few scenarios.